Results: Pure Health Holding PJSC Exceeded Expectations And The Consensus Has Updated Its Estimates

Pure Health Holding PJSC (ADX:PUREHEALTH) just released its latest second-quarter results and things are looking bullish. The company beat forecasts, with revenue of د.إ7.6b, some 3.2% above estimates, and statutory earnings per share (EPS) coming in at د.إ0.07, 97% ahead of expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the current consensus from Pure Health Holding PJSC's six analysts is for revenues of د.إ30.9b in 2026. This would reflect an okay 7.9% increase on its revenue over the past 12 months. Statutory per share are forecast to be د.إ0.19, approximately in line with the last 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of د.إ31.0b and earnings per share (EPS) of د.إ0.18 in 2026. So the consensus seems to have become somewhat more optimistic on Pure Health Holding PJSC's earnings potential following these results.

View our latest analysis for Pure Health Holding PJSC

The consensus price target was unchanged at د.إ3.64, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Pure Health Holding PJSC at د.إ5.45 per share, while the most bearish prices it at د.إ2.45. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 17% growth on an annualised basis. That is in line with its 20% annual growth over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 11% per year. So it's pretty clear that Pure Health Holding PJSC is forecast to grow substantially faster than its industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Pure Health Holding PJSC's earnings potential next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Pure Health Holding PJSC analysts - going out to 2028, and you can see them free on our platform here.

You can also see our analysis of Pure Health Holding PJSC's Board and CEO remuneration and experience, and whether company insiders have been buying stock.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.